Close
Alethia

Molecular assay for the detection of C. difficile. Alethia provides a quick, accurate and reliable molecular assay for C. difficile detection.

Catalog Number: 480050

Support & Documents

Why Alethia?

Alethia provides a versatile workflow that can help labs of any size function at their best. With Alethia, your core lab, hospital lab, reference lab, or physician’s office lab can run more efficiently and deliver accurate results to clinicians and patients.

  • Group 12 Created with Sketch.
    Quick
  • Group 13 Created with Sketch.
    Accurate
  • Group 19 Created with Sketch.
    Reliable

Support & Documents

Our support materials aim to be as comprehensive as our C. difficile testing solutions.

Downloadable PDFs

Webinars & Videos

FAQs

Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.

Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.

Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.

There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.

The 2018 MDRO/CDI Protocol states that the results of the final tests that are placed in the patient’s medical record should be used to determine whether or not the event meets the CDI LabID Event definition. That means that facilities using a multi-step testing algorithm for C. difficile will be entering LabID events in NHSN based on the results of the final test in the algorithm. In 2017, the CDI testing algorithm of “NAAT plus EIA, if NAAT-positive” received the “NAAT” level of risk adjustment. Now the CDI testing algorithm of “NAAT plus EIA, if NAAt-positive” is assigned the “EIA” level of risk adjustment. Facilities using this algorithm should only enter CDI LabID events into NHSN if the results from the EIA test are positive.

  1. https://www.cdc.gov/cdiff/clinicians/faq.html#anchor_1529601758264
  2. L Clifford McDonald, Dale N Gerding, Stuart Johnson, Johan S Bakken, Karen C Carroll, Susan E Coffin, Erik R Dubberke, Kevin W Garey, Carolyn V Gould, Ciaran Kelly, Vivian Loo, Julia Shaklee Sammons, Thomas J Sandora, Mark H Wilcox; Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clinical Infectious Diseases, Volume 66, Issue 7, 19 March 2018, Pages e1–e48, https://doi.org/10.1093/cid/cix1085
  3. https://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf

 

Alethia C. difficile – 87493

Definitive answers, confidence in results

Contact Sales

Definitive answers, confidence in results

Contact Sales

Para-Pak

The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn more.

Learn More

“The fact that Meridian could offer all three assays to help us improve our diagnoses and treatment, that was a big plus. The C. difficile and Group B Strep were our priorities, and this platform filled those needs.” “It’s all been so much better — less worry about missed positives and a better workflow all around.”

A Community Hospital

Get in touch with us

Contact Us

Welcome to

Please select your country to continue

Continue